Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve

This important step comes as a result of Bespak’s commitment to looking beyond low Global Warming Potential (GWP) propellants for opportunities to reduce carbon footprint in the pharma industry.

The completion of Bespak’s first LCA marks a significant milestone that has been achieved as part of Bespak’s overarching sustainability strategy. It follows Bespak’s investment in manufacturing capabilities at clinical and commercial scale for low carbon pMDIs incorporating the low GWP propellants, HFA-152a & HFO-1234ze.